2015


To access this material please log in or register

Register Authorize
2015/№5

Autoimmune cardiomyopathy: a myth or reality?

Khashchevskaya D. A., Mitrofanova L. B., Ignatjeva E. S., Konovalov P. V., Malikov K. N., Lebedev D. S., Zverev D. A., Moiseeva O. M.
Federal State Budgetary Institution, “North-West Federal Medical Research Center” of the RF Ministry of Health Care, Akkuratova 2, St. Petersburg 97341

Keywords: autoantibody, autoimmune cardiomyopathy, myocarditis

DOI: 10.18087 / rhfj.2015.5.2105

Background. Diversity of clinical manifestations of myocardial inflammatory disease and the need for morphological confirmation of diagnosis explain the difficulties which a physician encounters in examination and treatment of such patients. Aim. Comparative analysis of data from clinical and instrumental examination of patients with morphologically documented autoimmune cardiomyopathy (CMP) and lymphocytic myocarditis. Materials and methods. 11 patients with morphologically documented autoimmune CMP and 11 patients with active lymphocytic myocarditis and minimal HLA-DR expression were examined. Standard EchoCG study, contrast-enhanced magnetic resonance imaging, and endomyocardial biopsy (EMB) with immunogenic analysis were performed for all patients. Profile of circulating marker cardiotropic autoantibodies (autoAB) was determined, and biopsy samples were examined for cardiotropic viruses using molecular genetic methods. Results. Patients of two groups differed in the amount of myocardium-infiltrating CD3+-lymphocytes and pronouncement of the HLA-DR expression. 36 % of patients with documented myocarditis had cardiomyocyte necrosis associated with a higher detection frequency of the viral genome (64 %). The immunohistochemical analysis showed that the expression of myocardial immunoglobulins M (IgM) was observed only in patients with autoimmune CMP. Patients with autoimmune CMP had higher titers of autoAB to cytoskeletal and cytoplasmic proteins of cardiomyocytes and lower titers of autoAB to epitopes of adenine nucleotide translocator (ANT) than patients of the myocarditis group. Along with that, levels of circulating autoAB to β1-adrenoceptors and М2-cholinoreceptors were increased. According to data of contrast-enhanced MRI, a combination of two criterial signs for myocarditis (myocardial edema on T2‑weighted image and late contrast enhancement) was observed in 29 % of patients with autoimmune CMP and in 50 % of patients with myocarditis. Conclusion. It cannot be excluded that autoimmune CMP is only a specific case of the autoimmune inflammatory process in the myocardium, which could not be detected by EMB due to mosaicism of the process. The degree of myocardial inflammatory infiltration and the HLA-DR expression depend on the status of cell / humoral immunity and can be genetically determined.
  1. Caforio AL, Pankuweit S, Arbustini E, Basso C, Gimeno-Blanes J, Felix SB et al. Current state of knowledge on aetiology, diagnosis, management, and therapy of myocarditis: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2013 Sep;34 (33):2636–48.
  2. Friedrich MG, Sechtem U, Schulz-Menger J, Holmvang G, Alakija P, Cooper LT et al. Cardiovascular magnetic resonance in myocarditis: a JACC white paper. J Am Coll Cardiol. 2009 Apr 28;53 (17):1475–87.
  3. Hundley WG, Bluemke DA, Finn JP, Flamm SD, Fogel MA, Friedrich MG et al. ACCF / ACR / AHA / NASCI / SCMR 2010 expert consensus document on cardiovascular magnetic resonance: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. J Am Coll Cardiol. 2010 Jun 8;55 (23):2614–62.
  4. Dennert R, Crijns HJ, Heymans S. Acute viral myocarditis. Eur Heart J. 2008 Sep;29 (17):2073–82.
  5. Chow LH, Radio SJ, Sears TD, McManus B. M. Insensitivity of right ventricular endomyocardial biopsy in the diagnosis of myocarditis. J Am Coll Cardiol. 1989 Oct;14 (4):915–20.
  6. Hauck AJ, Kearney DL, Edwards WD. Evaluation of postmortem endomyocardial biopsy specimens from 38 patients with lymphocytic myocarditis: implications for role of sampling error. Mayo Clin Proc. 1989 Oct;64 (10):1235–45.
  7. Chimenti C, Frustaci A. Contribution and risks of left ventricular endomyocardial biopsy in patients with cardiomyopathies: a retrospective study over a 28‑year period. Circulation. 2013 Oct 1;128 (14):1531–41.
  8. Witebsky E, Rose NR. Studies on organ specificity. VII. Production of antibodies to rabbit thyroid by injection of foreign thyroid extracts. J Immunol. 1959 Jul;83 (1):41–8.
  9. Caforio AL, Tona F, Bottaro S, Vinci A, Dequal G, Daliento L et al. Clinical implications of anti-heart autoantibodies in myocarditis and dilated cardiomyopathy. Autoimmunity. 2008 Feb;41 (1):35–45.
  10. Leuschner F, Li J, Göser S, Reinhardt L, Ottl R, Bride P et al. Absence of auto-antibodies against cardiac troponin I predicts improvement of left ventricular function after acute myocardial infarction. Eur Heart J. 2008 Aug;29 (16):1949–55.
  11. Diepenhorst GM, Ciurana CL, Diaz Padilla N, Boekholdt SM, Krijnen PA, Lagrand WK et al. IgM antibodies against apoptotic cells and phosphorylcholine in patients with acute myocardial infarction in relation to infarct size and inflammatory response. Adv Clin Exp Med. 2012 Jul-Aug;21 (4):455–67.
  12. Caforio AL, Mahon NG, Baig MK, Tona F, Murphy RT, Elliott PM, McKenna WJ. Prospective familial assessment in dilated cardiomyopathy: cardiac autoantibodies predict disease development in asymptomatic relatives. Circulation. 2007 Jan 2;115 (1):76–83.
  13. Caforio AL, Mahon NJ, Tona F, McKenna WJ. Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance. Eur J Heart Fail. 2002 Aug;4 (4):411–7.
  14. Stavrakis S, Kem DC, Patterson E, Lozano P, Huang S, Szabo B et al. Opposing cardiac effects of autoantibody activation of beta-adre­nergic and M2 muscarinic receptors in cardiac-related diseases. Int J Cardiol. 2011 May 5;148 (3):331–6.
  15. Рогова М. М., Миронова Н. А., Родионова Е. С., Малкина Т. А., Зыков К. А., Беспалова Ж. Д. и др. Титры антител к β1‑адрено­рецепторам и М2‑холинорецепторам у больных с желудочковыми нарушениями ритма сердца без признаков органического заболевания сердечно-сосудистой системы и их возможное клиническое значение. Рациональная фармакотерапия в кардиологии. 2012;8 (5):647–54.
  16. Iwata M, Yoshikawa T, Baba A, Anzai T, Mitamura H, Ogawa S. Autoantibodies against the second extracellular loop of beta1‑adrenergic receptors predict ventricular tachycardia and sudden death in patients with idiopathic dilated cardiomyopathy. J Am Coll Cardiol. 2001 Feb;37 (2):418–24.
  17. Du Y, Yan L, Wang J, Zhan W, Song K, Han X et al. β1-adrenoceptor autoantibodies from DCM patients enhance the proliferation of T-lymphocytes through the β1‑AR / cAMP / PKA and p38 MAPK pathways. PLoS One. 2012;7 (12):e52911.
  18. Li Y, Heuser JS, Cunningham LC, Kosanke SD, Cunningham MW. Mimicry and antibody-mediated cell signaling in autoimmune myocarditis. J Immunol. 2006 Dec 1;177 (11):8234–40.
  19. Ventéo L, Bourlet T, Renois F, Douche-Aourik F, Mosnier JF, Maison GL et al. Enterovirus-related activation of the cardiomyocyte mitochondrial apoptotic pathway in patients with acute myocarditis. Eur Heart J. 2010 Mar;31 (6):728–36.
  20. Liu Y, Zhu H, Su Z, Sun C, Yin J, Yuan H et al. IL-17 contributes to cardiac fibrosis following experimental autoimmune myocarditis by a PKCβ / Erk1 / 2 / NF-κB-dependent signaling pathway. Int Immunol. 2012 Oct;24 (10):605–12.
  21. Yuan J, Yu M, Lin QW, Cao AL, Yu X, Dong JH et al. Neutralization of IL-17 inhibits the production of anti-ANT autoantibodies in CVB3‑induced acute viral myocarditis. Int Immunopharmacol. 2010 Mar;10 (3):272–6.
  22. Neu N, Rose NR, Beisel KW, Herskowitz A, Gurri-Glass G, Graig SW. Cardiac myosin induces myocarditis in genetically predisposed mice. J Immunol. 1987 Dec 1;139 (11):3630–6.
  23. Leuschner F, Katus HA, Kaya Z. Autoimmune myocarditis: past, present and future. J Autoimmun. 2009 Nov-Dec;33 (3-4):282–9.
  24. Hufnagel G, Maisch B. Expression of MHC class I and II antigens and the Il-2 receptor in rejection, myocarditis and dilated cardiomyopathy. Eur Heart J. 1991 Aug;12 (Suppl D): 137–40.
  25. Caforio AL, Stewart JT, Bonifacio E, Burke M, Davies MJ, McKenna WJ, Bottazzo GF. Inappropriate major histocompatibility complex expression on cardiac tissue in dilated cardiomyopathy. Relevance for autoimmunity? JAutoimmun. 1990 Apr;3 (2):187–200.
  26. Li WM, Liu W, Gao C, Zhou BG. Immunoregulatory effects of atorvastatin on experimental autoimmune myocarditis in Lewis rats. Immunol Cell Biol. 2006 Jun;84 (3):274–80.
  27. Guardiola J, Maffei A. Control of MHC class II gene expression in autoimmune, infectious, and neoplastic diseases. Crit Rev Immunol. 1993;13 (3-4):247–68.
  28. Irla M, Hugues S, Gill J, Nitta T, Hikosaka Y, Williams IR et al. Autoantigen-specific interactions with CD4+ thymocytes control mature medullary thymic epithelial cell cellularity. Immunity. 2008 Sep 19;29 (3):451–63.
  29. Otten LA, Leibundgut-Landmann S, Huarte J, Kos-Braun IC, Lavanchy C, Barras E et al. Revisiting the specificity of the MHC class II transactivator CIITA in vivo. Eur J Immunol. 2006 Jun;36 (6):1548–58.
  30. Meder B, Rühle F, Weis T, Homuth G, Keller A, Franke J et al. A genome-wide association study identifies 6p21 as novel risk locus for dilated cardiomyopathy. Eur Heart J. 2014 Apr;35 (16):1069–77.
  31. Smith SC, Allen PM. The role of T cells in myosin-induced autoimmune myocarditis. Clin Immunol Immunopathol. 1993 Aug;68 (2):100–6.
  32. Collado JA, Guitart C, Ciudad MT, Alvarez I, Jaraquemada D. The Repertoires of Peptides Presented by MHC–II in the Thymus and in Peripheral Tissue: A Clue for Autoimmunity? Front Immunol. 2013 Dec 17;4:442.
  33. Schwartz J, Winters JL, Padmanabhan A, Balogun RA, Delaney M, Linenberger ML et al. Guidelines on the use of herapeutic aphe­resis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the sixth special issue. J Clin Apher. 2013 Jul;28 (3):145–284.
  34. Winters JL. American Society for Apheresis guidelines on the use of apheresis in clinical practice: practical, concise, evidence-based recommendations for the apheresis practitioner. J Clin Apher. 2014 Aug;29 (4):191–3.
  35. Dandel M, Wallukat G, Englert A, Lehmkuhl HB, Knosalla C, Hetzer R. Long-term benefits of immunoadsorption in β1‑adreno­ceptor autoantibody-positive transplant candidates with dilated cardiomyopathy. Eur J Heart Fail. 2012 Dec;14 (12):1374–88.
Khashchevskaya D. A., Mitrofanova L. B., Ignatjeva E. S., Konovalov P. V., Malikov K. N., Lebedev D. S. et al. Autoimmune cardiomyopathy: a myth or reality? Russian Heart Failure Journal. 2015;16 (5):288–295

To access this material please log in or register

Register Authorize
Ru En